SRA 737
Alternative Names: CCT-245737; PNT-737; SRA737Latest Information Update: 12 Jun 2023
Price :
$50 *
At a glance
- Originator Cancer Research Technology; Sareum; The Institute of Cancer Research
- Developer Sierra Oncology
- Class Antineoplastics; Morpholines; Nitriles; Pyrazines; Pyridines; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Ovarian cancer; Prostate cancer
- No development reported Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from preclinical studies in Prostate cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 07 Dec 2022 No development reported - Phase-II for Solid tumours (Combination therapy, Late-stage disease) in United Kingdom (PO)
- 07 Dec 2022 No development reported - Phase-II for Solid tumours (Late-stage disease, Monotherapy) in United Kingdom (PO)